FSTX logo

F-star Therapeutics (FSTX) Stock

Profile

Full Name:

F-star Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

06 May 2016

Indexes:

Not included

Website:

http://www.f-star.com

Description:

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$21.17 M(+88.05% YoY)

Annual EPS

-$1.88(+80.60% YoY)

PE Ratio

-

Annual ROE

-44.74%

Annual Debt To Equity

0.10

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 10, 2023

Recent annual earnings:

Mar 14, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

15 July '22 HC Wainwright & Co.
Neutral
24 June '22 SVB Leerink
Market Perform
11 May '22 SVB Leerink
Outperform
17 Mar '22 HC Wainwright & Co.
Buy
17 Aug '21 SVB Leerink
Outperform
08 July '21 SVB Leerink
Outperform
09 June '21 B. Riley Securities
Buy
18 May '21 HC Wainwright & Co.
Buy
16 Apr '21 Oppenheimer
Outperform
08 Apr '21 William Blair
Outperform

Screeners with FSTX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$18.72
FSTX price is currently at an all-time high

Price Analysts Target

$7.00
FSTX price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-25.26%
FSTX annual revenue is down -25.26% over the past 3 years

Annual Revenue Estimate

$4.34 M
FSTX annual revenue is currently +387.72% higher than the consensus analysts' forecast

Annual Net Income 3-Year Change

-35.94%
FSTX annual net profit is down -35.94% over the past 3 years

Annual EPS 3-Year Change

+25.9%
FSTX annual earnings per share is up +25.9% over the past 3 years

Annual EPS Estimate

-$2.47
FSTX annual earnings per share is currently -23.89% lower than the consensus analysts' forecast

Annual Operating Profit

-$30.71 M
FSTX annual operaing income is -$30.71 million

Annual Operating Profit 3-Year Change

-67.42%
FSTX annual operaing income is down -67.42% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-44.74%
FSTX annual return on equity is -44.74%

Annual ROA

-33.52%
FSTX annual return on assets is -33.52%

Annual EBIT

-$30.81 M
FSTX annual earnings before interest & taxes is -$30.81 million

Annual EBITDA

-$30.17 M
FSTX annual earnings before interest, taxes, depreciation & amortization is -$30.17 million

Annual Interest Coverage Ratio

-36.51
FSTX annual interest coverage ratio is -36.51

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

6.98
FSTX annual current ratio is 6.98

Annual Total Assets

$123.02 M
FSTX annual total assets is $123.02 million

Annual Current Assets

$84.74 M
FSTX annual total current assets is $84.74 million

Annual Total Liabilities

$26.16 M
FSTX annual total liabilities is $26.16 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-23.32%
FSTX annual cash flow from operations is down -23.32% over the past 3 years

Annual CFI 3-Year Change

-111.97%
FSTX annual cash flow from investing activities is down -111.97% over the past 3 years

Annual CFF 3-Year Change

+564.2%
FSTX annual cash flow from financing activities is up +564.2% over the past 3 years

Annual CAPEX

$658.00 K
FSTX annual capital expenditures is $658.00 thousand

Annual CAPEX 3-Year Change

+418.11%
FSTX annual capital expenditures is up +418.11% over the past 3 years

Annual FCF

-$27.93 M
FSTX annual free cash flow is -$27.93 million

Annual FCF 3-Year Change

-25.57%
FSTX annual free cash flow is down -25.57% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of F-star Therapeutics?
  • What is the ticker symbol for F-star Therapeutics?
  • Does F-star Therapeutics pay dividends?
  • What sector is F-star Therapeutics in?
  • What industry is F-star Therapeutics in?
  • What country is F-star Therapeutics based in?
  • When did F-star Therapeutics go public?
  • Is F-star Therapeutics in the S&P 500?
  • Is F-star Therapeutics in the NASDAQ 100?
  • Is F-star Therapeutics in the Dow Jones?
  • When was F-star Therapeutics's last earnings report?
  • When does F-star Therapeutics report earnings?
  • Should I buy F-star Therapeutics stock now?

What is the primary business of F-star Therapeutics?

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.

What is the ticker symbol for F-star Therapeutics?

The ticker symbol for F-star Therapeutics is NASDAQ:FSTX

Does F-star Therapeutics pay dividends?

No, F-star Therapeutics does not pay dividends

What sector is F-star Therapeutics in?

F-star Therapeutics is in the Healthcare sector

What industry is F-star Therapeutics in?

F-star Therapeutics is in the Biotechnology industry

What country is F-star Therapeutics based in?

F-star Therapeutics is headquartered in United Kingdom

When did F-star Therapeutics go public?

F-star Therapeutics's initial public offering (IPO) was on 06 May 2016

Is F-star Therapeutics in the S&P 500?

No, F-star Therapeutics is not included in the S&P 500 index

Is F-star Therapeutics in the NASDAQ 100?

No, F-star Therapeutics is not included in the NASDAQ 100 index

Is F-star Therapeutics in the Dow Jones?

No, F-star Therapeutics is not included in the Dow Jones index

When was F-star Therapeutics's last earnings report?

F-star Therapeutics's most recent earnings report was on 10 May 2023

When does F-star Therapeutics report earnings?

The date for F-star Therapeutics's next earnings report has not been announced yet

Should I buy F-star Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions